Match!
François Bertucci
French Institute of Health and Medical Research
CancerPathologyCancer researchBreast cancerMedicine
322Publications
52H-index
8,842Citations
What is this?
Publications 316
Newest
#1Patricia Pautier (Institut Gustave Roussy)H-Index: 39
#2Anne FloquetH-Index: 28
Last. Sophie Piperno-Neumann (Curie Institute)H-Index: 34
view all 20 authors...
Source
#1Axel Le Cesne (Institut Gustave Roussy)H-Index: 1
#2Claire CropetH-Index: 14
Last. Mélodie CarbonnauxH-Index: 1
view all 18 authors...
Source
#1Mathias Neron (ICM Partners)
#2Christophe Sajous (UCBL: Claude Bernard University Lyon 1)H-Index: 1
Last. Nelly Firmin (University of Montpellier)H-Index: 1
view all 20 authors...
Background Metastatic phyllodes tumors have poor prognosis with median overall survival of 11.5 months. The objective of this study is to identify prognostic factors and the best options for management of metastatic malignant phyllode tumors (MMPTs).
1 CitationsSource
Background An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not all cancer types. The reason of this differential prognostic connotation remains unknown. Methods To explore the contextual prognostic value of cancer immune phenotypes, we applied a multimodal pan-cancer analysis among 31 different histologies (9282 patients), encompassing immune and oncogenic tran...
Source
#2Pascal FinettiH-Index: 43
Last. Heloisa KomechenH-Index: 3
view all 21 authors...
The SF-1 transcription factor target gene FATE1 encodes a cancer-testis antigen that has an important role in regulating apoptosis and response to chemotherapy in adrenocortical carcinoma (ACC) cells. Autoantibodies directed against FATE1 were previously detected in patients with hepatocellular carcinoma. In this study, we investigated the prevalence of circulating anti-FATE1 antibodies in pediatric and adult patients with adrenocortical tumors using three different methods (immunofluorescence, ...
Source
#1C Rypens (University of Antwerp)H-Index: 2
#2François BertucciH-Index: 52
Last. Peter B. VermeulenH-Index: 50
view all 12 authors...
Inflammatory breast cancer (IBC) is an aggressive and poorly characterized breast cancer subtype with few targets available for molecular therapy. Several attempts aimed at characterizing the disease at the genomic, transcriptomic and proteomic level. Together, these studies suggest that MYC is central to the biology of IBC. Here, we analyzed data sets from patient samples and preclinical models to corroborate this hypothesis. Genomic and transcriptomic profiles were obtained using next-generati...
Source
#1Nicolas Penel (university of lille)H-Index: 41
#2Olivier MirH-Index: 30
Last. Jean-Yves BlayH-Index: 78
view all 20 authors...
Abstract Background Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib. Patients and methods This double-blind, placebo-controlled, multicenter comparative randomized phase II trial included patients with histologically proven advanced and inoperable STS. Patients receiving placebo were offered optional cr...
Source
#1Mathias Neron (ICM Partners)
#2Christophe Sajous (UCBL: Claude Bernard University Lyon 1)H-Index: 1
Last. Charles Honoré (Institut Gustave Roussy)H-Index: 23
view all 20 authors...
The optimal threshold of surgical margins for breast malignant phyllodes tumors (MPTs) and the impact of adjuvant chemotherapy and radiotherapy were investigated. We conducted a multicenter nationwide retrospective study of all MPT cases with central pathological review within the French Sarcoma Group. Endpoints were local recurrence-free survival (LRFS), metastasis-free survival (MFS), and overall survival (OS) rates. Overall, 212 patients were included in the study. All non-metastatic patients...
2 CitationsSource
#1Sophie Piperno-Neumann (Curie Institute)H-Index: 34
Last. Jean-Yves BlayH-Index: 78
view all 20 authors...
Source
#1Clémence BasseH-Index: 1
#2Antoine ItalianoH-Index: 44
Last. Jean-Yves BlayH-Index: 78
view all 39 authors...
Source
12345678910